Condition 1: Myocardial Infarction. Condition 2: type 2 diabetes. ST elevation (STEMI) myocardial infarction of unspecified site Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: In this group, 25 type 2 diabetic patients treated with oral drugs, and they will receive empagliflozin from ABIDI Pharmaceutical Company in the form of 10 mg tabl
Sponsors
Zanjan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: type 2 diabetes patients with Hb A1C: 6.5-8 treated with metformin, sulfonyl urea ore combination of both of this medicines patients with Typic chest pain during the 12 hours before the visit that lasted longer than 30 minutes, along with an ST-segment elevation above 0.1 mV in two leads or more in ECG
Exclusion criteria
Exclusion criteria: cardiogenic shock hypoglycemia diabetic ketoacidosis History of Coronary Artery Bypass Surgery type 1 diabetic patient sever liver failure patient with end stage cancer history of sever allergic reaction to Empagliflozin or its formulation components Severe renal failure (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis hypovolemia any inflammatory under treatment disease history of any cancer advanced heart failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Empagliflozin on cardiotrophin-1 expression. Timepoint: before intervention and 12 weeks after intervention. Method of measurement: Real-time polymerase chain reaction.;Empagliflozin on growth differentiation factor-15 expression. Timepoint: before intervention and 12 weeks after intervention. Method of measurement: Real-time polymerase chain reaction. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Rastgoo
Zanjan University of Medical Sciences
Outcome results
None listed